INVITATION
Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
INVITATION
Takeda - Oncogenic drivers in advanced NSCLC: Navigating an evolving landscape to optimize patient outcomes
INVITATION
MSD - Redefining survival expectations in NSCLC
INVITATION
Bristol Myers Squibb - Exploring the current and evolving landscape in thoracic cancers
INVITATION
AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
INVITATION
TouchIME - PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities